TARS Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. (TARS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 82% planned / 18% discretionary
Largest single sale: $877.4K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Lin Elizabeth Yeu 4 fills | Chief Medical Officer | Sell 10b5-1 | 13,953 | $87.50 | $1.2M | 7,933 −63.8% of holding | |
| Azamian Bobak R. 2 fills | President/CEO and Board Chair | Sell 10b5-1 | 10,000 | $90.56 | $905.6K | 830,891 −1.2% of holding | |
| Neervannan Seshadri | Chief Operating Officer | Sell 10b5-1 | 4,564 | $85.00 | $387.9K | 78,532 −5.5% of holding | |
| Azamian Bobak R. 2 fills | President/CEO and Board Chair | Sell 10b5-1 | 10,000 | $61.55 | $615.5K | 853,409 −1.2% of holding | |
| Farrow Jeffrey S | See Remarks | Sell | 14,396 | $60.95 | $877.4K | 56,801 −20.2% of holding | |
| LINK WILLIAM J PHD 2 fills | Director | Sell 10b5-1 | 12,500 | $62.12 | $776.5K | 108,714 −10.3% of holding | |
| Goodrich Katherine | Director | Sell 10b5-1 | 2,954 | $62.08 | $183.4K | 2,233 −57% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.